Literature DB >> 24733266

Paraneoplastic neuromyelitis optica spectrum disorder associated with metastatic carcinoid expressing aquaporin-4.

Michelle Figueroa1, Yong Guo2, Alexandros Tselis1, Sean J Pittock2, Vanda A Lennon3, Claudia F Lucchinetti2, Robert P Lisak4.   

Abstract

IMPORTANCE: Reports of neuromyelitis optica spectrum disorder (NMOSD) occurring in the setting of neoplasia suggest that aquaporin-4 autoimmunity may in some cases have a paraneoplastic basis. OBSERVATIONS: In this case report, we describe a patient with NMOSD whose test results were seropositive for aquaporin-4 IgG and who had a hepatic metastasis from a small-bowel neuroendocrine tumor. The tumor cells expressed aquaporin-4 immunoreactivity. She presented to the Neurology Department at Wayne State University with bilateral leg weakness, ascending paresthesias, and decreased sensation. CONCLUSIONS AND RELEVANCE: This case extends the context of NMOSD as a paraneoplastic disorder.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24733266      PMCID: PMC4076888          DOI: 10.1001/jamaneurol.2013.6331

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  19 in total

Review 1.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

2.  Amphiphysin autoimmunity: paraneoplastic accompaniments.

Authors:  Sean J Pittock; Claudia F Lucchinetti; Joseph E Parisi; Eduardo E Benarroch; Bahram Mokri; Christina L Stephan; Kwang-Kuk Kim; Manfred W Kilimann; Vanda A Lennon
Journal:  Ann Neurol       Date:  2005-07       Impact factor: 10.422

Review 3.  Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG.

Authors:  Shelley A Cross; Diva R Salomao; Joseph E Parisi; Thomas J Kryzer; Elizabeth A Bradley; Jonathan A Mines; Byron L Lam; Vanda A Lennon
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

4.  Aquaporin-4 autoantibodies in a paraneoplastic context.

Authors:  Sean J Pittock; Vanda A Lennon
Journal:  Arch Neurol       Date:  2008-05

5.  Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome.

Authors:  Sean J Pittock; Thomas J Kryzer; Vanda A Lennon
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

6.  Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma.

Authors:  Marina Frasquet; Luis Bataller; Estefanía Torres-Vega; María Durán-Moreno; José M García-Verdugo; Teresa Sevilla; Salvador Rivas; Francisco Pérez-Miralles; María Simó-Castelló; Bonaventura Casanova
Journal:  J Neuroimmunol       Date:  2013-07-27       Impact factor: 3.478

Review 7.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

8.  Neuromyelitis optica and non organ-specific autoimmunity.

Authors:  Sean J Pittock; Vanda A Lennon; Jerome de Seze; Patrick Vermersch; Henry A Homburger; Dean M Wingerchuk; Claudia F Lucchinetti; Hélène Zéphir; Kevin Moder; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2008-01

9.  Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G.

Authors:  B Mark Keegan; Sean J Pittock; Vanda A Lennon
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

10.  Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues.

Authors:  A Frigeri; M A Gropper; F Umenishi; M Kawashima; D Brown; A S Verkman
Journal:  J Cell Sci       Date:  1995-09       Impact factor: 5.285

View more
  11 in total

1.  Paraneoplastic Neuromyelitis Optica Associated with Lung Adenocarcinoma in a Young Woman.

Authors:  Kyoung Won Baik; Se Hoon Kim; Ha Young Shin
Journal:  J Clin Neurol       Date:  2018-04       Impact factor: 3.077

Review 2.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

3.  Neuromyelitis optica spectrum disorder and adenocarcinoma of ovary: a novel association.

Authors:  Julie Sachdeva; Ramandeep Bansal; Aastha Takkar; Rajveer Singh
Journal:  BMJ Case Rep       Date:  2019-04-24

4.  Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.

Authors:  Maria Sepúlveda; Nuria Sola-Valls; Domingo Escudero; Bojan Rojc; Manuel Barón; Luis Hernández-Echebarría; Begoña Gómez; Josep Dalmau; Albert Saiz; Francesc Graus
Journal:  Mult Scler       Date:  2017-09-18       Impact factor: 6.312

Review 5.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

Review 6.  Aquaporin-4 autoimmunity.

Authors:  Anastasia Zekeridou; Vanda A Lennon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-05-21

7.  Screening for onconeural antibodies in neuromyelitis optica spectrum disorders.

Authors:  Benjamin Berger; Tilman Hottenrott; Sebastian Rauer; Oliver Stich
Journal:  BMC Neurol       Date:  2017-01-10       Impact factor: 2.474

8.  Neuromyelitis optica spectrum disorder coincident with renal clear cell carcinoma: A case report.

Authors:  Haiqiang Jin; Hongjun Hao; Ding Nan; Jingjing Luo; Lei Wang; Feng Gao; Yining Huang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

Review 9.  Ocular Paraneoplastic Syndromes.

Authors:  Joanna Przeździecka-Dołyk; Anna Brzecka; Maria Ejma; Marta Misiuk-Hojło; Luis Fernando Torres Solis; Arturo Solís Herrera; Siva G Somasundaram; Cecil E Kirkland; Gjumrakch Aliev
Journal:  Biomedicines       Date:  2020-11-10

Review 10.  AQP4-IgG positive paraneoplastic NMOSD: A case report and review.

Authors:  Manqiu Ding; Yue Lang; Li Cui
Journal:  Brain Behav       Date:  2021-09-14       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.